Cargando…
Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1)
Titled the “most destructive of all cancers”, pancreatic cancer is a malignant tumor with a very poor prognosis and has a poor response to systemic therapy. At present, several studies have shown that tegafur-gimeracil-oteracil potassium (hereinafter referred to as TS-1) is no less superior to gemci...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283868/ https://www.ncbi.nlm.nih.gov/pubmed/35847852 http://dx.doi.org/10.3389/fonc.2022.862600 |
_version_ | 1784747427508518912 |
---|---|
author | Luo, Dongcheng Liao, Sina Li, Qian Lin, Youzhi Wei, Junbao Li, Yongqiang Liao, Xiaoli |
author_facet | Luo, Dongcheng Liao, Sina Li, Qian Lin, Youzhi Wei, Junbao Li, Yongqiang Liao, Xiaoli |
author_sort | Luo, Dongcheng |
collection | PubMed |
description | Titled the “most destructive of all cancers”, pancreatic cancer is a malignant tumor with a very poor prognosis and has a poor response to systemic therapy. At present, several studies have shown that tegafur-gimeracil-oteracil potassium (hereinafter referred to as TS-1) is no less superior to gemcitabine in the treatment of advanced pancreatic cancer. In addition, a number of current clinical studies have shown that targeted therapy combined with chemotherapy reflects therapeutic advantages in pancreatic cancer. Moreover, in vitro and in vivo experiments have also demonstrated that anlotinib can curb the proliferation of pancreatic cancer cells and induce their apoptosis. Here, we report for the first time that a patient with locally advanced pancreatic cancer achieved good efficacy after switching to TS-1 chemotherapy combined with anlotinib targeted therapy. Previously, the disease of the patient still rapidly progressed without control following the first switch to abraxane combined with gemcitabine chemotherapy (AG regimen) due to the progression after chemo-radiotherapy. In this case, the patient achieved progression-free survival (PFS) of over 14 months via the treatment with anlotinib targeted therapy combined with TS-1 chemotherapy and secondary radiotherapy (prior to secondary radiotherapy, the patient achieved a PFS of nearly 12 months via the treatment with oral anlotinib combined with TS-1). Up to now, the progress of the disease is ceased. The oral administration of targeted therapy and chemotherapy are still in progress and the general condition of the patient is good. This suggests that patients with advanced pancreatic cancer may benefit from treatment with the anlotinib targeted therapy combined with TS-1 chemotherapy. |
format | Online Article Text |
id | pubmed-9283868 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92838682022-07-16 Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1) Luo, Dongcheng Liao, Sina Li, Qian Lin, Youzhi Wei, Junbao Li, Yongqiang Liao, Xiaoli Front Oncol Oncology Titled the “most destructive of all cancers”, pancreatic cancer is a malignant tumor with a very poor prognosis and has a poor response to systemic therapy. At present, several studies have shown that tegafur-gimeracil-oteracil potassium (hereinafter referred to as TS-1) is no less superior to gemcitabine in the treatment of advanced pancreatic cancer. In addition, a number of current clinical studies have shown that targeted therapy combined with chemotherapy reflects therapeutic advantages in pancreatic cancer. Moreover, in vitro and in vivo experiments have also demonstrated that anlotinib can curb the proliferation of pancreatic cancer cells and induce their apoptosis. Here, we report for the first time that a patient with locally advanced pancreatic cancer achieved good efficacy after switching to TS-1 chemotherapy combined with anlotinib targeted therapy. Previously, the disease of the patient still rapidly progressed without control following the first switch to abraxane combined with gemcitabine chemotherapy (AG regimen) due to the progression after chemo-radiotherapy. In this case, the patient achieved progression-free survival (PFS) of over 14 months via the treatment with anlotinib targeted therapy combined with TS-1 chemotherapy and secondary radiotherapy (prior to secondary radiotherapy, the patient achieved a PFS of nearly 12 months via the treatment with oral anlotinib combined with TS-1). Up to now, the progress of the disease is ceased. The oral administration of targeted therapy and chemotherapy are still in progress and the general condition of the patient is good. This suggests that patients with advanced pancreatic cancer may benefit from treatment with the anlotinib targeted therapy combined with TS-1 chemotherapy. Frontiers Media S.A. 2022-07-01 /pmc/articles/PMC9283868/ /pubmed/35847852 http://dx.doi.org/10.3389/fonc.2022.862600 Text en Copyright © 2022 Luo, Liao, Li, Lin, Wei, Li and Liao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Luo, Dongcheng Liao, Sina Li, Qian Lin, Youzhi Wei, Junbao Li, Yongqiang Liao, Xiaoli Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1) |
title | Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1) |
title_full | Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1) |
title_fullStr | Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1) |
title_full_unstemmed | Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1) |
title_short | Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1) |
title_sort | case report: a case of locally advanced pancreatic cancer which achieved progression free for over 12 months by subsequent therapy with anlotinib hydrochloride plus tegafur-gimeracil-oteracil potassium (ts-1) |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283868/ https://www.ncbi.nlm.nih.gov/pubmed/35847852 http://dx.doi.org/10.3389/fonc.2022.862600 |
work_keys_str_mv | AT luodongcheng casereportacaseoflocallyadvancedpancreaticcancerwhichachievedprogressionfreeforover12monthsbysubsequenttherapywithanlotinibhydrochlorideplustegafurgimeraciloteracilpotassiumts1 AT liaosina casereportacaseoflocallyadvancedpancreaticcancerwhichachievedprogressionfreeforover12monthsbysubsequenttherapywithanlotinibhydrochlorideplustegafurgimeraciloteracilpotassiumts1 AT liqian casereportacaseoflocallyadvancedpancreaticcancerwhichachievedprogressionfreeforover12monthsbysubsequenttherapywithanlotinibhydrochlorideplustegafurgimeraciloteracilpotassiumts1 AT linyouzhi casereportacaseoflocallyadvancedpancreaticcancerwhichachievedprogressionfreeforover12monthsbysubsequenttherapywithanlotinibhydrochlorideplustegafurgimeraciloteracilpotassiumts1 AT weijunbao casereportacaseoflocallyadvancedpancreaticcancerwhichachievedprogressionfreeforover12monthsbysubsequenttherapywithanlotinibhydrochlorideplustegafurgimeraciloteracilpotassiumts1 AT liyongqiang casereportacaseoflocallyadvancedpancreaticcancerwhichachievedprogressionfreeforover12monthsbysubsequenttherapywithanlotinibhydrochlorideplustegafurgimeraciloteracilpotassiumts1 AT liaoxiaoli casereportacaseoflocallyadvancedpancreaticcancerwhichachievedprogressionfreeforover12monthsbysubsequenttherapywithanlotinibhydrochlorideplustegafurgimeraciloteracilpotassiumts1 |